Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDER Director Woodcock Plans Changes To Drug Reviews During OND Transition

Executive Summary

In podcast interview, US FDA’s Center for Drug Evaluation & Research Director Janet Woodcock discusses her plans the Office of New Drugs, including changes to the structure of the office to make reviews better managed and more uniform across divisions. Woodcock says she expects to stay in the interim OND role for most of 2017.

Advertisement

Related Content

Woodcock's 'Bias' In Sarepta Case Made Jenkins Worry About Future Drug Reviews
Woodcock Wants Rapid Regulatory Policy Development
Autism Feedback To FDA: Focus On Communication, Redefine 'Irritability'
A Hiring Freeze By A Different Name: OMB Wants Agency 'Workforce Reduction' Plans
Gottlieb's FDA: Specialized Groups Could Create Review Consistency, Speed
Biosimilars: Next User Fee Cycle Will Be Judged On US FDA's Approvals, Rep. Burgess Says
Gottlieb Nomination As US FDA Chief Could Signal Changes To Generic Approval Process
Gottlieb Nomination As US FDA Chief Could Signal Changes To Generic Approval Process
Orphan Drug Act: Congressional, FDA, NORD Reviews Come Amid Pricing Debate
Jenkins' Retirement From US FDA Was Several Years In The Making

Topics

Advertisement
UsernamePublicRestriction

Register

PS120173

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel